Kwality Pharmaceuticals has notified BSE Limited of an upcoming board meeting, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled to be held on Tuesday, May 19, 2026, at 10:30 A.M. at Village Nagkalan, Majitha Road, Amritsar, to consider and approve the company's audited financial results.

Board Meeting Details

The following key details have been disclosed regarding the scheduled board meeting:

Trading Window Closure

In line with the company's earlier communication dated March 26, 2026, and in accordance with the Company's Code of Conduct for Prohibition of Insider Trading framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, a trading window restriction is currently in effect. The trading window for dealing in securities of the company will remain closed for all Board of Directors, Designated Persons, and their immediate relatives until 48 hours after the financial results are made public on May 19, 2026.

The intimation was submitted to the Department of Corporate Services, BSE Limited, and signed by Ramesh Kumar, Managing Director (DIN: 00462656), on behalf of Kwality Pharmaceuticals.

Kwalitity Pharmaceuticals Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with BSE Limited on April 08, 2026, fulfilling its regulatory obligations under the Securities and Exchange Board of India framework.

Regulatory Compliance Certificate

The certificate was issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates that companies confirm the proper handling of securities received for dematerialization during each quarter.

Certificate Details

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 06, 2026. The certificate confirms that all securities received from depository participants for dematerialization up to March 31, 2026 were properly confirmed to the depositories.

The registrar verified that:

• Securities received for dematerialization were accepted or rejected as appropriate
• All securities are listed on stock exchanges where previously issued securities are traded
• Security certificates were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members within the required 15-day timeframe

Corporate Compliance

Gurpreet Kaur, Company Secretary and Compliance Officer, submitted the certificate to BSE Limited's Department of Corporate Services. The submission ensures the company maintains its compliance status with SEBI's depositories and participants regulations.

This quarterly filing represents part of the company's ongoing regulatory compliance obligations, ensuring transparency in share dematerialization processes and maintaining good standing with market regulators and stock exchanges.